Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

Carboplatin 12Paclitaxel 11Gemcitabine 11Capecitabine 7Irinotecan 6Fluorouracil 5Cisplatin 5Radiotherapy 4Oxaliplatin 4Leucovorin 4Bevacizumab 4pembrolizumab 3Filgrastim 3Etoposide 3Erlotinib Hydrochloride 3Cyclophosphamide 3etoposide phosphate 2atezolizumab 2Trastuzumab 2Topotecan 2Taxes 2Surveys and Questionnaires 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Genetic Testing 2FAPI-46 2Docetaxel 2CP protocol 2Amifostine 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Unknown Primary × Bevacizumab × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00458315 2015-05-08

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Rigshospitalet, Denmark

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193622 2010-09-17

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡